• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    PetMed Express Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Financial Statements and Exhibits

    7/3/25 8:36:16 AM ET
    $PETS
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples
    Get the next $PETS alert in real time by email
    pets-20250702
    0001040130FALSE00010401302025-07-022025-07-02

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549
    FORM 8-K
    CURRENT REPORT
    Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
    Date of report (Date of earliest event reported): July 2, 2025
    PetMed Express, Inc.
    (Exact name of registrant as specified in its charter)
    Florida
    000-28827
    65-0680967
    (State or other jurisdiction
    of incorporation)
    (Commission
    File Number)
    (I.R.S. Employer
    Identification No.)
    420 South Congress Avenue, Delray Beach, Florida 33445
    (Address of principal executive offices) (Zip Code)
    (561) 526-4444
    (Registrant’s telephone number, including area code)
    Not Applicable
    (Former name or former address, if changed since last report)
    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
    o
    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
    o
    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
    o
    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
    o
    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
    Securities registered pursuant to Section 12(b) of the Act:
    Title of each class
    Trading Symbol(s)
    Name of each exchange on which registered
    Common Stock, par value $.001 per share
    PETS
    NASDAQ Global Select Market
    Preferred Stock Purchase RightsN/A
    NASDAQ Global Select Market
    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
    Emerging growth company o
    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o



    Item 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing.

    As previously disclosed, PetMed Express, Inc. (the “Company”) determined that it was unable, without unreasonable effort or expense, to file its Annual Report on Form 10-K for the fiscal year ended March 31, 2025 (the “Form 10-K”) by the prescribed due date because the Company is continuing to compile, review, and analyze the information necessary to complete its financial statements and related disclosures to be included in the Form 10-K, as more fully described in the Company’s Current Report on Form 8-K filed with the Securities and Exchange Commission (“SEC”) on July 1, 2025.

    On July 2, 2025, the Company received an expected notice (the “Notice”) from The Nasdaq Stock Market LLC (“Nasdaq”) indicating that, as a result of not having timely filed the Form 10-K with the SEC, the Company is not in compliance with Nasdaq Listing Rule 5250(c)(1) (the “Listing Rule”), which requires timely filing of all required periodic financial reports with the SEC.

    The Notice has no immediate effect on the listing or trading of the Company’s common stock on Nasdaq.

    The Notice indicated that the Company must submit a plan to regain compliance with the Listing Rule within 60 calendar days, or by September 1, 2025, and following receipt of such plan, Nasdaq may grant an exception of up to 180 calendar days from the Form 10-K due date, or until December 29, 2025, for the Company to regain compliance.

    While the Company can provide no assurances as to timing, the Company is working diligently to complete its financial statements for its fiscal year ending March 31, 2025, and the Form 10-K and plans to file the Form 10-K as soon as practicable to regain compliance with the Listing Rule.

    On July 3, 2025, the Company issued a press release announcing its receipt of the Notice. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and incorporated by reference herein.


    Item 9.01 Financial Statements and Exhibits.
    (d)Exhibits.
    Exhibit No.
    Description
    99.1
    Press release dated July 3, 2025
    104
    Cover Page Interactive Data File (embedded within the Inline XBRL document)


    Cautionary Note Regarding Forward-Looking Statements

    This Current Report on Form 8-K contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements contained in this Current Report on Form 8-K that do not relate to matters of historical fact should be considered forward-looking statements. Words such as “may,” “could,” “expect,” “project,” “outlook,” “strategy,” “intend,” “plan,” “seek,” “anticipate,” “believe,” “estimate,” “predict,” “potential,” “strive,” “goal,” “continue,” “likely,” “will,” “would” and other similar words and expressions are intended to signify forward-looking statements. Such forward-looking statements are necessarily based upon estimates and assumptions that, while considered reasonable by the Company and its management, are inherently uncertain and are subject to various risks and uncertainties, including: statements regarding the Company’s ability to complete the filing of the Form 10-K within the anticipated time period; the Company’s ability to regain compliance with Nasdaq listing standards; and the time and effort required to complete the Company’s financial statements for its fiscal year ending March 31, 2025. The Company’s future results may also be impacted by other risk factors listed from time to time in the Company’s filings with the SEC, including, but not limited to, the Company's Annual Report on Form 10-K for the year ended March 31, 2024, as well as other subsequent filings on Form 10-Q and periodic filings on Form 8-K. You should not place undue reliance on these forward-looking statements, which apply only as of the date of this Current Report on Form 8-K and should not be relied upon as representing the Company’s views as of any subsequent date. The Company explicitly disclaims any obligation to update any forward-looking statements, other than as may be required by law. If the Company does update one or more forward-looking statements, no inference should be made that the Company will make additional updates with respect to those or other forward-looking statements.

    2


    SIGNATURES
    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
    Dated: July 3, 2025
    PETMED EXPRESS, INC.
    By:
    /s/ Robyn D’Elia
    Name:
    Robyn D’Elia
    Title:
    Chief Financial Officer and Treasurer
    3
    Get the next $PETS alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $PETS

    DatePrice TargetRatingAnalyst
    5/25/2023$20.00Buy
    Lake Street
    1/25/2022$25.00 → $21.00Underweight
    Morgan Stanley
    1/20/2022$32.00Neutral → Buy
    Sidoti
    11/18/2021$25.00Underweight
    Morgan Stanley
    10/1/2021$28.00Hold
    Jefferies
    8/5/2021$22.00Underperform
    Credit Suisse
    More analyst ratings

    $PETS
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Large owner Silvercape Investments Ltd bought $9,071 worth of shares (2,817 units at $3.22), increasing direct ownership by 0.12% to 2,311,230 units (SEC Form 4)

      4 - PETMED EXPRESS INC (0001040130) (Issuer)

      7/3/25 10:19:05 AM ET
      $PETS
      Retail-Drug Stores and Proprietary Stores
      Consumer Staples
    • Large owner Silvercape Investments Ltd bought $2,228 worth of shares (694 units at $3.21), increasing direct ownership by 0.03% to 2,308,413 units (SEC Form 4)

      4 - PETMED EXPRESS INC (0001040130) (Issuer)

      7/2/25 2:41:27 PM ET
      $PETS
      Retail-Drug Stores and Proprietary Stores
      Consumer Staples
    • Large owner Nina Capital Holdings Inc. bought $98,375 worth of shares (25,000 units at $3.94), increasing direct ownership by 0.99% to 2,550,000 units (SEC Form 4)

      4 - PETMED EXPRESS INC (0001040130) (Issuer)

      6/4/25 4:15:58 PM ET
      $PETS
      Retail-Drug Stores and Proprietary Stores
      Consumer Staples

    $PETS
    SEC Filings

    See more
    • PetMed Express Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Financial Statements and Exhibits

      8-K - PETMED EXPRESS INC (0001040130) (Filer)

      7/3/25 8:36:16 AM ET
      $PETS
      Retail-Drug Stores and Proprietary Stores
      Consumer Staples
    • PetMed Express Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits

      8-K - PETMED EXPRESS INC (0001040130) (Filer)

      7/1/25 8:37:12 AM ET
      $PETS
      Retail-Drug Stores and Proprietary Stores
      Consumer Staples
    • PetMed Express Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - PETMED EXPRESS INC (0001040130) (Filer)

      6/16/25 8:37:04 AM ET
      $PETS
      Retail-Drug Stores and Proprietary Stores
      Consumer Staples

    $PETS
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Lake Street initiated coverage on PetMed Express with a new price target

      Lake Street initiated coverage of PetMed Express with a rating of Buy and set a new price target of $20.00

      5/25/23 9:17:49 AM ET
      $PETS
      Retail-Drug Stores and Proprietary Stores
      Consumer Staples
    • Morgan Stanley reiterated coverage on PetMed Express with a new price target

      Morgan Stanley reiterated coverage of PetMed Express with a rating of Underweight and set a new price target of $21.00 from $25.00 previously

      1/25/22 10:17:17 AM ET
      $PETS
      Retail-Drug Stores and Proprietary Stores
      Consumer Staples
    • PetMed Express upgraded by Sidoti with a new price target

      Sidoti upgraded PetMed Express from Neutral to Buy and set a new price target of $32.00

      1/20/22 9:13:56 AM ET
      $PETS
      Retail-Drug Stores and Proprietary Stores
      Consumer Staples

    $PETS
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • PetMed Express Receives Notification of Deficiency from Nasdaq Related to Delayed Filing of Annual Report on Form 10-K

      DELRAY BEACH, Fla., July 03, 2025 (GLOBE NEWSWIRE) -- PetMed Express, Inc. ("PetMeds®") (NASDAQ:PETS) received on July 2, 2025, an expected notice (the "Notice") from The Nasdaq Stock Market LLC ("Nasdaq") indicating that, as a result of not having timely filed its Annual Report on Form 10-K for the fiscal year ended March 31, 2025 (the "Form 10-K"), with the Securities and Exchange Commission ("SEC"), the Company is not in compliance with Nasdaq Listing Rule 5250(c)(1) (the "Listing Rule"), which requires timely filing of all required periodic financial reports with the SEC. The Notice has no immediate effect on the listing or trading of the Company's common stock on Nasdaq. The Notice

      7/3/25 8:30:00 AM ET
      $PETS
      Retail-Drug Stores and Proprietary Stores
      Consumer Staples
    • PetMed Express, Inc. Provides Update on Status of Fourth Quarter and FY 2025 Results and Form 10-K Filing

      DELRAY BEACH, Fla., July 01, 2025 (GLOBE NEWSWIRE) -- PetMed Express, Inc. (the "Company") dba PetMeds and parent company of PetCareRx (NASDAQ:PETS) today provided an update on the status of its fourth quarter and FY 2025 results and 10-K filing. On June 16, 2025, the Company filed a Form 12b-25 (the "Form 12b-25") disclosing that the Company would be unable to file its Form 10-K for the year ended March 31, 2025 (the "2025 Form 10-K") within the prescribed period without unreasonable effort or expense. The extension period provided under Rule 12b-25 expires on July 1, 2025. The Company will be unable to file its 2025 Form 10-K within the extension period because the Company is continuing

      7/1/25 8:30:00 AM ET
      $PETS
      Retail-Drug Stores and Proprietary Stores
      Consumer Staples
    • Wagmo Partners with PetMeds® to Bring Everyday Pet Health Savings to Members

      New partnership gives Wagmo members savings on prescriptions, supplements and everyday pet health essentials Wagmo, the pet healthcare benefit trusted by leading employers, today announced a new partnership with PetMed Express, Inc., parent company of PetMeds and PetCareRx (NASDAQ:PETS). Through this collaboration, Wagmo members now have access to exclusive savings on a wide range of pet health products, ranging from nutritional foods, tasty treats and vet-trusted medications to supplements and daily care essentials for dogs and cats. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250624773408/en/ The partnership enhances Wagm

      6/24/25 9:00:00 AM ET
      $PETS
      Retail-Drug Stores and Proprietary Stores
      Consumer Staples

    $PETS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Large owner Silvercape Investments Ltd bought $9,071 worth of shares (2,817 units at $3.22), increasing direct ownership by 0.12% to 2,311,230 units (SEC Form 4)

      4 - PETMED EXPRESS INC (0001040130) (Issuer)

      7/3/25 10:19:05 AM ET
      $PETS
      Retail-Drug Stores and Proprietary Stores
      Consumer Staples
    • Large owner Silvercape Investments Ltd bought $2,228 worth of shares (694 units at $3.21), increasing direct ownership by 0.03% to 2,308,413 units (SEC Form 4)

      4 - PETMED EXPRESS INC (0001040130) (Issuer)

      7/2/25 2:41:27 PM ET
      $PETS
      Retail-Drug Stores and Proprietary Stores
      Consumer Staples
    • Large owner Nina Capital Holdings Inc. bought $98,375 worth of shares (25,000 units at $3.94), increasing direct ownership by 0.99% to 2,550,000 units (SEC Form 4)

      4 - PETMED EXPRESS INC (0001040130) (Issuer)

      6/4/25 4:15:58 PM ET
      $PETS
      Retail-Drug Stores and Proprietary Stores
      Consumer Staples

    $PETS
    Leadership Updates

    Live Leadership Updates

    See more
    • PetMeds® to Ring Nasdaq Opening Bell in Celebration of National Pet Day on April 11th

      DELRAY BEACH, Fla., April 11, 2025 (GLOBE NEWSWIRE) -- In celebration of National Pet Day, PetMed Express, Inc. (NASDAQ:PETS)—the original consumer pet healthcare company serving dogs, cats, and horses for nearly 30 years—will ring the Nasdaq Opening Bell this Friday, April 11, 2025. This momentous occasion honors the powerful bond between people and their pets and will feature adoptable rescue dogs from Bidawee, one of the nation's oldest no-kill animal welfare organizations. It's a tribute to the joy and unconditional love pets bring into our lives–and a reminder of how many still await families of their own. "Our pets are more than just animals; they are family," said Sandra Campo

      4/11/25 9:00:00 AM ET
      $PETS
      Retail-Drug Stores and Proprietary Stores
      Consumer Staples
    • PetMed Express, Inc. Announces Appointment of Peter Batushansky to Board of Directors

      Former pet industry executive with more than 20 years of experience across retail, pet, healthcare, and private equity Third independent director to join the Board since 2024 Longtime board member and former Chairman Dr. Gian Fulgoni will retire DELRAY BEACH, Fla., April 09, 2025 (GLOBE NEWSWIRE) -- PetMed Express, Inc., parent company of PetMeds and PetCareRx, (NASDAQ:PETS) (the "Company") today announced the appointment of Peter Batushansky to the Company's Board of Directors ("the Board"), effective April 09, 2025. Mr. Batushansky is currently a Partner at L2 Capital Partners and brings to the Board more than 20 years of experience across retail, pet, healthcare and private equity, i

      4/9/25 8:00:00 AM ET
      $PETS
      Retail-Drug Stores and Proprietary Stores
      Consumer Staples
    • PetMed Express, Inc. Announces Appointment of Robyn D'Elia as Chief Financial Officer

      DELRAY BEACH, Fla., Sept. 12, 2024 (GLOBE NEWSWIRE) -- PetMed Express, Inc., dba PetMeds and parent company of PetCareRx, (NASDAQ:PETS) (the "Company") today announced the appointment of retail and ecommerce veteran Robyn D'Elia as Chief Financial Officer ("CFO") effective September 16, 2024. D'Elia brings over 25 years of experience in financial leadership and strategic planning across multiple industries, including 24 years at Bed Bath & Beyond where she served in senior leadership roles across finance for two decades, and served as CFO from 2018 to 2020. Most recently D'Elia served as CFO at Odeko, a privately held all-in-one operations partner for independent coffee shops, cafes and ot

      9/12/24 8:00:00 AM ET
      $PETS
      Retail-Drug Stores and Proprietary Stores
      Consumer Staples

    $PETS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by PetMed Express Inc.

      SC 13G - PETMED EXPRESS INC (0001040130) (Subject)

      11/14/24 4:02:14 PM ET
      $PETS
      Retail-Drug Stores and Proprietary Stores
      Consumer Staples
    • SEC Form SC 13G filed by PetMed Express Inc.

      SC 13G - PETMED EXPRESS INC (0001040130) (Subject)

      10/10/24 6:26:43 PM ET
      $PETS
      Retail-Drug Stores and Proprietary Stores
      Consumer Staples
    • SEC Form SC 13G/A filed by PetMed Express Inc. (Amendment)

      SC 13G/A - PETMED EXPRESS INC (0001040130) (Subject)

      2/13/24 5:12:03 PM ET
      $PETS
      Retail-Drug Stores and Proprietary Stores
      Consumer Staples

    $PETS
    Financials

    Live finance-specific insights

    See more
    • PetMed Express, Inc. Announces Preliminary Fourth Quarter and FY 2025 Results and Filing of Form 12b-25

      DELRAY BEACH, Fla., June 16, 2025 (GLOBE NEWSWIRE) -- PetMed Express, Inc. dba PetMeds and parent company of PetCareRx (NASDAQ:PETS) today announced preliminary fourth quarter and fiscal year 2025 results and filed Form 12b-25, Notification of Late Filing, with the Securities and Exchange Commission. The Company is unable to file its Annual Report on Form 10-K for the fiscal year ended March 31, 2025 within the prescribed time period without unreasonable effort or expense. The Company expects to file its Annual Report on Form 10-K with the Securities and Exchange Commission as soon as practicable, and no later than July 1, 2025, in accordance with Rule 12b-25. Preliminary Fourth Quarter

      6/16/25 8:30:00 AM ET
      $PETS
      Retail-Drug Stores and Proprietary Stores
      Consumer Staples
    • PetMed Express, Inc. Announces Delay in Fourth Quarter and Fiscal Year End Earnings Release and Conference Call

      DELRAY BEACH, Fla., June 10, 2025 (GLOBE NEWSWIRE) -- PetMed Express, Inc. dba PetMeds and parent company of PetCareRx (NASDAQ:PETS) today announced it is delaying the release of the Company's fourth quarter and fiscal year 2025 earnings release and subsequent conference call, which had been scheduled for June 10, 2025, because the Company requires additional time to complete the year-end audit process. The Company anticipates that it will issue the earnings release, hold the related conference call, and file its Annual Report on Form 10-K as soon as possible, but no later than June 16, 2025. About PetMed Express, Inc. Founded in 1996, PetMeds is a leader in pioneering the digital pet p

      6/10/25 4:05:00 PM ET
      $PETS
      Retail-Drug Stores and Proprietary Stores
      Consumer Staples
    • PetMed Express, Inc. Sets Fourth Quarter and Full Fiscal Year 2025 Earnings Call

      DELRAY BEACH, Fla., May 27, 2025 (GLOBE NEWSWIRE) -- PetMed Express, Inc., dba PetMeds and parent company of PetCareRx, (NASDAQ:PETS) will hold a conference call on Tuesday, June 10, 2025 at 4:30pm Eastern Time to discuss its financial results for the fourth quarter and full fiscal year ended March 31, 2025. Financial results will be issued in a press release prior to the call. PETS management will host the conference call, followed by a question-and-answer period. Please call the conference telephone number 5-10 minutes prior to the start time. Date: Tuesday, June 10, 2025Time: 4:30pm Eastern Time (1:30pm Pacific Time)U.S. dial-in number: 877-407-0789International number: 201-689-8562We

      5/27/25 4:05:00 PM ET
      $PETS
      Retail-Drug Stores and Proprietary Stores
      Consumer Staples